A multidisciplinary clinical team led by Professor Bernat Soria from the Institute of Bioengineering at the Miguel Hernández University of Elche (UMH, Spain) has developed a new method to deliver cell ...

Telix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed.

Adding intravenous thrombolysis to endovascular treatment is not associated with an increased risk for bleeding or with changes in functional outcomes in patients with carotid tandem lesions.

A multidisciplinary clinical team led by Professor Bernat Soria from the Institute of Bioengineering at the Miguel Hernández ...

IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam ...

Over five years, relapsing-remitting multiple sclerosis patients in France taking Tysabri have adopted more at-home dosing, a review found.

The following is a summary of "Incidence of Clinically Significant Ventricular Arrhythmias in Patients on Home Inotrope Infusion in the Contemporary Era," published in the March 2025 issue of American ...

Revelstoke Capital Partners has made a significant investment in AOM Infusion, a US-based specialty infusion provider focused on chronic therapy management. No financial terms were disclosed. AOM ...

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

But IV nutrition therapy has also become popular among the wellness crowd in recent years, thanks to potential perks such as fighting fatigue, boosting immunity, and easing stress. IV nutrition ...

The gene therapy BBM-H901 (dalnacogene ponparvovec) has been approved in China for adults with moderate to severe hemophilia ...